AI-Native Scoping Reviews & Evidence Mapping

PAD is not just undertreated — it is systematically undertreated despite repeated signals that proper medication changes survival, cardiovascular risk, and limb outcomes. This review shows where the real gaps are, which therapies carry the strongest signal, and why better discharge and follow-up prescribing may be one of the most actionable opportunities in vascular care.

This paper shows that PAD does not affect women and men in the same way: women are often treated less aggressively and face more perioperative complications, while men more often carry the burden of amputation, mortality, and severe limb outcomes. The full paper is worth reading because it makes clear where the true gender gap lies in PAD—not just in prevalence, but in diagnosis, treatment, and what happens after intervention.

This review shows that anticoagulation in PAD is not a simple “more is better” story: low-dose rivaroxaban plus aspirin delivers the clearest reduction in limb and cardiovascular events, but the benefit is tightly linked to patient selection and bleeding risk. The full read is worth it because it maps exactly where dual pathway inhibition is strongest, where full-dose or nonspecific anticoagulation may backfire, and how PAD changes the antithrombotic strategy in real-world settings like revascularization, VTE overlap, and atrial fibrillation.

This paper shows that PAD risk is driven mainly by smoking and diabetes, but is also strongly shaped by age, hypertension, dyslipidemia, inflammation, and social disadvantage. The full paper is worth reading because it makes clear which factors matter most, which newer risk signals are emerging, and why PAD is still too often missed despite its major impact on limb loss and cardiovascular death.

This review shows that PAD bypass outcomes are driven less by the operation alone than by who the patient is going into it: dialysis, CKD, conduit choice, and post-operative management repeatedly shape survival, limb outcomes, and graft durability. The full read is worth it because it clarifies where bypass still holds its strongest advantage over endovascular therapy, which patients benefit most, and which risk signals should change decisions before and after surgery.

PAD-related amputation is rarely caused by one factor alone: this evidence map shows how diabetes, tissue loss, kidney disease, delayed vascular assessment, undertreatment, and social inequality converge to decide who loses a limb. The full review highlights which therapies, warning signs, and limb-preservation pathways may reduce major amputation risk before the window for salvage is lost.

The aim of this paper is to synthesize research findings on the risk factors for the development of mesenteric ischemia and the clinical, laboratory, and radiological predictors of mortality and intestinal necrosis in affected patients. The review utilises 213 original studies with 1362960 total participants (topic deduplicated ΣN). The evidence map suggests that mesenteric ischemia risk and prognosis are dominated by a recurring triad of systemic vulnerability, hemodynamic compromise, and markers of advanced bowel injury. Among the clearest signals, lactate thresholds above 2–3 mmol/L, SOFA v…

To synthesize current evidence regarding the clinical efficacy, biological mechanisms, and patient-centered outcomes of larval therapy in the management of acute and chronic wounds across human and animal models. The review utilises 94 original studies with 12244 total participants (topic deduplicated ΣN). Across the mapped evidence, larval therapy emerged most consistently as a rapid biological debridement strategy, with reported signals including a 92.3% wound-healing rate in post-revascularization ischemic wounds versus 18.2% with vacuum-assisted closure at one month, median free-range debr…

IVUS is not simply “better imaging” — this review shows where intravascular ultrasound changes real outcomes: complex coronary PCI, long lesions, diabetic ACS, femoropopliteal intervention, and iliofemoral venous disease. The full paper is worth reading because it maps when IVUS should be selectively adopted, when routine use adds little, and where AI-driven and hybrid intravascular imaging may define the next generation of endovascular precision.

This paper shows that the ischemic penumbra is not just a fading border around stroke core, but a dynamic and biologically active therapeutic target whose fate depends on collaterals, metabolism, BBB integrity, and how fast true reperfusion is achieved. The full read is worth it because it separates the real clinical signal from the hype—showing where tissue-based stroke decisions already work, where imaging and software still disagree, and which next-generation strategies may actually preserve salvageable brain.

This paper shows that Gritti-Stokes amputation may offer more than limb removal alone: in selected patients it appears to preserve a more stable, functional stump with surprisingly strong links to prosthetic fitting, mobility, and even longer-term survival. The full paper is worth reading because it clarifies where this old technique still has real modern value, which patients may benefit most, and why its outcomes may compare more favorably than many assume.

This paper shows that GLP-1 receptor agonists are no longer just metabolic drugs: across a broad evidence base, they emerge as cardioprotective therapies linked to lower MACE, stroke, mortality, and even limb events, with signals extending from atherosclerosis to heart failure and vascular biology. The full paper is worth reading because it distinguishes where the cardiovascular benefit is strongest, where arrhythmic and perioperative uncertainties remain, and why underuse in real-world practice may be limiting their true impact.